• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

    2/13/24 5:06:22 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMGN alert in real time by email
    SC 13G/A 1 tv01170-immunogeninc.htm SCHEDULE 13G/A immunogeninc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 6)*

    Name of issuer:  ImmunoGen Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  45253H101

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  45253H101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    321,537

    7.  SOLE DISPOSITIVE POWER

    24,891,055

    8.  SHARED DISPOSITIVE POWER

    575,895

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    25,466,950

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.13%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    ImmunoGen Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    830 Winter Street
    Waltham, MA 02451-1477

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    45253H101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $IMGN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IMGN

    DatePrice TargetRatingAnalyst
    12/1/2023$25.00 → $31.00Buy → Neutral
    Guggenheim
    11/20/2023$17.00Neutral
    Goldman
    11/9/2023$25.00Buy
    Deutsche Bank
    10/6/2023$16.00Perform
    Oppenheimer
    5/3/2023$6.00 → $16.00Neutral → Overweight
    Piper Sandler
    11/21/2022$10.00Buy
    Truist
    9/9/2022$8.00Overweight
    Barclays
    3/21/2022$9.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $IMGN
    SEC Filings

    See more
    • SEC Form 15-12G filed by ImmunoGen Inc.

      15-12G - ImmunoGen, Inc. (0000855654) (Filer)

      2/22/24 4:15:19 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by ImmunoGen Inc.

      S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

      2/12/24 4:33:11 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by ImmunoGen Inc.

      S-8 POS - ImmunoGen, Inc. (0000855654) (Filer)

      2/12/24 4:32:20 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 26, 2024 - FDA Roundup: March 26, 2024

      For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

      3/26/24 3:38:14 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ELAHERE issued to IMMUNOGEN INC

      Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

      3/22/24 1:48:21 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for ELAHERE issued to IMMUNOGEN INC

      Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

      11/15/22 5:01:07 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mitchell Dean J returned 103,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:48:55 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Peterson Kristine

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:48:14 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thackray Helen M. returned 3,074 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ImmunoGen, Inc. (0000855654) (Issuer)

      2/12/24 4:47:26 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Financials

    Live finance-specific insights

    See more
    • AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

      Proposed acquisition will accelerate AbbVie's entry into the commercial market for ovarian cancerELAHERE® is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancerImmunoGen's late-stage development programs for ELAHERE provide opportunity to expand into earlier lines of therapy and additional patient populationsImmunoGen's follow-on pipeline complements AbbVie's oncology portfolio, which has the potential to be transformative across multiple solid tumors and hematologic malignanciesTransaction valued at $31.26 per share in cash, for a total equity value of approximately $10.1 billionAbbVie to hold an investor conference call at 8:00 a.m. CTNORTH CHICAGO

      11/30/23 7:30:00 AM ET
      $ABBV
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

      Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3 ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets Primary Endpoint of Objective Response Rate; Full Data Anticipated in Mid-2024 Advanced Geographic Market Expansion Through Collaboration with Takeda to Develop and Commercialize ELAHERE in Japan and Acceptance of NDA by the NMPA in China Expanded Leadership Team with Appointments of Lauren White, Chief Financial Officer, and Heather Adkins Huet, Chief Scientific Officer Conference Call to be Held at 8:00 a.m. E

      11/2/23 6:30:00 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results

      ImmunoGen Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third quarter 2023 operating results. Management will also provide a brief update on the business. CONFERENCE CALL INFORMATION To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location. ABOUT IMMUNOGEN

      10/19/23 4:01:00 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/14/24 5:01:40 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/14/24 4:26:22 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)

      SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)

      2/13/24 5:06:22 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ImmunoGen downgraded by Guggenheim with a new price target

      Guggenheim downgraded ImmunoGen from Buy to Neutral and set a new price target of $31.00 from $25.00 previously

      12/1/23 7:33:23 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on ImmunoGen with a new price target

      Goldman initiated coverage of ImmunoGen with a rating of Neutral and set a new price target of $17.00

      11/20/23 7:31:54 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Deutsche Bank initiated coverage on ImmunoGen with a new price target

      Deutsche Bank initiated coverage of ImmunoGen with a rating of Buy and set a new price target of $25.00

      11/9/23 6:40:12 AM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Antibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits Research

      New York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates deliver chemotherapy by fusing a linker to a monoclonal antibody that attaches to a specific target expressed on cancer cells. Inside the cancer cell, a poisonous chemical is released when the ADC attaches to its intended target (a cancer protein or receptor). Linkers, drugs or poisons, monoclonal antibodies, and others are among the most prevalent types of antibody-drug conjugates. A single white blood cell is cloned in order to produce monoclonal antibodies. Each successive antibody produced in this m

      1/22/25 11:05:00 AM ET
      $IMGN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $IMGN
    Leadership Updates

    Live Leadership Updates

    See more
    • PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

      11/5/24 7:05:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Seaport Therapeutics Names Lauren White as Chief Financial Officer

      Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

      11/5/24 7:00:00 AM ET
      $ABBV
      $CCCC
      $IMGN
      $NVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      ImmunoGen, Inc., (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 18, 2023, and in connection with the previously announced appointment of Ms. Lauren White as ImmunoGen's Senior Vice President and Chief Financial Officer, the compensation committee of the Company's Board of Directors (the "Compensation Committee") approved grants of non-qualified stock options to purchase 295,975 shares of its common stock and restricted stock units ("RSUs") covering 51,625 shares of its common stock under the Inducement Plan to Ms. White. The Inducement Plan is used exclusively for the grant of equity awards t

      9/18/23 5:00:00 PM ET
      $IMGN
      Biotechnology: Pharmaceutical Preparations
      Health Care